XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.3
Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Income Statement [Abstract]        
Net Revenue $ 26,333,819 $ 21,671,599 $ 75,572,167 $ 60,367,060
Cost of goods sold 1,874,214 1,991,987 5,646,463 5,890,719
Gross profit 24,459,605 19,679,612 69,925,704 54,476,341
Operating expenses        
Selling, general and administrative 19,877,875 17,420,347 58,641,402 51,453,311
Research and development 1,029,591 783,840 3,036,746 1,945,263
Depreciation and amortization 610,899 696,888 1,993,477 2,093,797
Change in fair value of earnout liabilities (14,451)
Total operating expenses 21,518,365 18,901,075 63,671,625 55,477,920
Operating income (loss) 2,941,240 778,537 6,254,079 (1,001,579)
Other income (expense)        
Interest expense (1,818,105) (927,577) (4,926,765) (1,839,259)
Share of losses from equity method investments (288,642) (31,448) (627,732) (31,448)
Interest income 3,672
Gain on disposal of property and equipment 10,932
Total other income (expense) [1] (2,106,747) (959,025) (5,539,893) (1,870,707)
Net income (loss) from continuing operations 834,493 (180,488) 714,186 (2,872,286)
Net loss from discontinued operations (including asset impairment charge of $26,472,407 in 2025) (Note 3) (31,246,601) (2,702,564) (36,672,075) (5,339,011)
Net loss (30,412,108) (2,883,052) (35,957,889) (8,211,297)
Net loss attributable to noncontrolling interest from continuing operations (955) (1,740) (5,197) (3,224)
Net loss attributable to noncontrolling interest from discontinued operations (23,544) (82,107)
Less: Total net loss attributable to noncontrolling interest (955) (25,284) (5,197) (85,331)
Net loss attributable to Sanara MedTech shareholders $ (30,411,153) $ (2,857,768) $ (35,952,692) $ (8,125,966)
Net income (loss) per share, basic:        
Continuing operations $ 0.10 $ (0.02) $ 0.08 $ (0.34)
Discontinued operations (3.62) (0.32) (4.26) (0.62)
Net income (loss) per share of common stock, basic (3.52) (0.34) (4.18) (0.96)
Net income (loss) per share, diluted:        
Continuing operations 0.09 (0.02) 0.08 (0.34)
Discontinued operations (3.49) (0.32) (4.12) (0.62)
Net income (loss) per share of common stock, diluted $ (3.40) $ (0.34) $ (4.04) $ (0.96)
Weighted average number of common shares outstanding, basic 8,646,668 8,517,381 8,610,538 8,468,394
Weighted average number of common shares outstanding, diluted 8,940,734 8,517,381 8,907,565 8,468,394
[1] For the three and nine months ended September 30, 2025 and 2024, other expense included interest expense and share of losses from equity method investments, offset by interest income and gain on disposal of property and equipment.